Stay updated with breaking news from Recommended Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction Overall... | May 11, 2023
Item 8.01Other Events. On May 11, 2023, Olema Pharmaceuticals, Inc. announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company's complete estrogen receptor ... | May 11, 2023
Operator: Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call. Please note, this event is being recorded.
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Operator: Welcome to the Immuneering Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.